HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION

Clinical trials for HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION explained in plain language.

Never miss a new study

Get alerted when new HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION trials appear

Sign up with your email to follow new studies for HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New gel aims to zap persistent HPV in women

Disease control Not yet recruiting

This study tests whether a gel called DARE-HPV can clear a persistent high-risk HPV infection in the genital area. About 118 premenopausal women aged 22-50 with a long-lasting infection will receive one of two doses of the gel for 14 or 21 days, or a placebo. The main goal is to …

Matched conditions: HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION

Phase: PHASE2 • Sponsor: Daré Bioscience, Inc. • Aim: Disease control

Last updated May 26, 2026 11:06 UTC

HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION

Get alerted when new HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION trials appear

New gel aims to zap persistent HPV in women